BETHESDA, Md., Dec. 1 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.
“BiTE antibodies represent a promising approach to cancer therapy,” said Dr. Karl Ziegelbauer, Head Therapeutic Research Oncology of Bayer Schering Pharma AG. “We are pleased with the progress of the program since the signing of the agreement in January of this year. We are looking forward to developing a new treatment for patients with solid tumors and to further advance novel therapeutic options in our oncology portfolio.”
About BiTE Antibodies
About Micromet, Inc.
Forward-Looking Statements
Micromet, Inc.
